The past 15 years have witnessed an explosion in the drugs market for multiple sclerosis (MS), enabling the first disease modifying therapies in the neurodegenerative disease market to become a reality.
As a result the MS market is the most lucrative of the neurodegenerative diseases, with Teva’s Copaxone (glatiramer acetate), Biogen’s Tecfidera (dimethyl fumarate) and Novartis’ Gilenya (fingolimod hydrochloride) each achieving worldwide revenues of over $3 billion in 2016.
The drugs work by targeting components of the immune system to decrease the severity of the immune attack.
Ocrevus – the first treatment for primary progressive MS
Pharmaceutical companies have capitalised on these market successes by continuing to investigate novel immunological targets and drugs.
In 2017, the FDA approved a new immunomodulator, Genetech’s ocrelizumab (Ocrevus), for the treatment of relapsing MS (RMS) and primary progressive MS (PPMS – a form of MS with no remissions).
In Phase III trials Ocrevus reduced the relapse rate in RMS by up to 47%, and reduced walking deterioration rates in PPMS to 38.9%, compared with placebo at 55.1%, over a period of 120 weeks.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Ocrevus is the 15th therapy approved by the FDA for the indication, and the first for the PPMS disease subtype.
Stem cell therapies – potential for a cure?
The Ottawa Hospital Research Institute in Canada is pioneering an entirely novel approach for the treatment of MS using immunoablation and bone marrow stem cell transplantation.
In 2000, a pioneering 24-person clinical trial was conducted on patients with advanced progressive forms of MS, with the aim of halting the progression of the disease and decreasing disability accumulation.
13 years later, 17 out of the 24 patients experienced either halting or reversal of their MS, with one patient previously confined to a wheelchair regaining independence and the ability to drive and work – vastly exceeding trial expectations.
However, many challenges remain regarding the safety and efficacy of the treatment; invasive surgery and long periods of recovery are both expensive and leave patients severely compromised, and one patient fatality was reported due to transplant complications within the study.
A new dawn for neurodegenerative diseases?
The successes seen in the MS market offer renewed optimism in the treatment of neurodegenerative diseases, and demonstrate the potential revenue opportunities for this therapy area.
Not only this, but the groundbreaking research conducted by the Ottawa Hospital Research Institute and others strongly indicates a cure for MS may soon become a reality.